A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
Choi JH, Kim KH, Roh KH, Jung H, Lee A, Lee JY, Song JY, Park SJ, Kim I, Lee WS, Seo SK, Choi IW, Fu YX, Yea SS, Park S.
Choi JH, et al. Among authors: roh kh.
Oncoimmunology. 2018 Jan 16;7(5):e1421890. doi: 10.1080/2162402X.2017.1421890. eCollection 2018.
Oncoimmunology. 2018.
PMID: 29721370
Free PMC article.